Paricalcitol vs. cinacalcet for secondary hyperparathyroidism in chronic kidney disease: A meta-analysis

Xu, Wei; Gong, Ling; Lu, Jingkui; Tang, Weigang

doi:10.3892/etm.2020.9044

Cited by 4 publications

(2 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In turn, in a meta-analysis by Xu et al, covering a total of 7 studies and 456 patients using paricalcitol and 412 patients treated with cinacalcet, the effectiveness of these drugs in lowering PTH levels in patients with SHPT was compared. There were no differences in the potential to lower PTH levels in the 2 analysed groups, a similar effect of both drugs on phosphate metabolism was found, and hypocalcaemia was observed much more often in the cinacalcet group [42]. In contrast, a comparison of the effects of 3 calcimimetics (cinacalcet, evocalcet, and etelcalcetide) based on 36 studies (11,247 participants; median follow-up = 26 weeks) the majority of dialysis patients (excluding 4 studies) showed that etelcalcetide had the best effect in lowering serum PTH levels, but causing more hypocalcaemia compared to other calcimimetics.…”

Section: Calcimimeticsmentioning

confidence: 67%

Secondary hyperparathyroidism in chronic kidney disease: pathomechanism and current treatment possibilities

Rodzoń-Norwicz,

Norwicz,

Sowa-Kućma

et al. 2023

Endokrynol Pol

View full text Add to dashboard Cite

circle. It should be emphasized here that the results of recent studies indicate that fibroblast growth factor 23 (FGF-23) and Klotho protein are the factors whose concentrations changes appear the earliest in the development of SHPT.The main and most dangerous complications of SHPT involve the skeletal and cardiovascular systems. Calcium and phosphate imbalances associated with CKD are defined by the Kidney Disease Improvement Global Outcomes (KDIGO) group as chronic kidney disease-metabolic bone disease (CKD-MBD). CKD-MBD includes bone complications that can lead to chronic pain syndromes and mobility limitations, cardiovascular complications, significantly increasing mortality in this group of patients, and soft tissue calcifications [1,2,3]. The last guidelines for the treatment of SHPT in the course of CKD were published by KDIGO in 2017 and have not been updated. This manuscript is a review of the literature published mainly after 2017, paying special attention to potentially new therapies that seem to be promising in the treatment of SHPT.

show abstract

Section: Calcimimeticsmentioning

confidence: 67%

Secondary hyperparathyroidism in chronic kidney disease: pathomechanism and current treatment possibilities

Rodzoń-Norwicz,

Norwicz,

Sowa-Kućma

et al. 2023

Endokrynol Pol

View full text Add to dashboard Cite

show abstract

“…The body tries to stimulate phosphaturia and improve the absorption of calcium by increasing PTH, but again with the problem of efficiency due to the resistance of cells to the action of PTH. A vicious cycle is created that ultimately leads to the development of secondary hyperparathyroidism (SHPT) with extremely high PTH, hyperphosphatemia and hypocalcemia that represent cardinal features of the advanced stage of HBB 4 .…”

Section: Introductionmentioning

confidence: 99%

The effect of paricalcitol and cinacalcet on parathyroid hormone in patients undergoing chronic hemodialysis and serum calcium and phosphorus oscillation

Osmanovic¹,

Rahimic²

2023

Magna Sci. Adv. Res. Rev.

View full text Add to dashboard Cite

Chronic kidney disease (CKD) is one of the leading public health problems in the world, and according to research conducted on different races and in different parts of the world, approximately one in 10 adults has some form of kidney damage. In stage 3 CKD, the kidneys lose the ability to remove excess phosphorus that accumulates in the body, leading to hyperphosphatemia, which promotes an increase in parathyroid hormone (PTH), and the appearance of secondary hyperparathyroidism. It is associated with increased morbidity and mortality and negatively affects the quality of life of patients with chronic kidney disease. It is generally considered that parathyroid hormone is a systemic "toxin" in CKD and its increased secretion is a sign of progression of kidney disease. Homeostasis of calcium and phosphorus is maintained through a complex connection between bones, intestines, kidneys and parathyroid glands. A retrospective - prospective study will be conducted in the hemodialysis center of the Živinice Health Center. 49 patients suffering from secondary hyperparathyroidism will be included in the study. Patients are of both sexes, aged 18 to 85 years. As part of secondary hyperparathyroidism in hemodialysis patients, 75.5% of patients had PTH values below 1000 pg/ml, while 24.5% had PTH values above 1000 pg/ml. A decrease in serum Ca and P values was recorded in 32% of subjects who were treated with paricalcitol. A decrease in serum Ca and P values was recorded in 56% of cases. Observing the effect of paricalcitol and cinacalcet, it is observed that the greatest reduction in PTH values in patients who had PTH values higher than 1000pg/ml - treated with cinacalcet is 44%.

show abstract

Effects of active vitamin D analogs and calcimimetic agents on PTH and bone mineral biomarkers in hemodialysis patients with SHPT: a network meta-analysis

Liu,

Zheng

et al. 2024

Eur J Clin Pharmacol

View full text Add to dashboard Cite

Paricalcitol vs. cinacalcet for secondary hyperparathyroidism in chronic kidney disease: A meta-analysis

Cited by 4 publications

References 27 publications

Secondary hyperparathyroidism in chronic kidney disease: pathomechanism and current treatment possibilities

Secondary hyperparathyroidism in chronic kidney disease: pathomechanism and current treatment possibilities

The effect of paricalcitol and cinacalcet on parathyroid hormone in patients undergoing chronic hemodialysis and serum calcium and phosphorus oscillation

Effects of active vitamin D analogs and calcimimetic agents on PTH and bone mineral biomarkers in hemodialysis patients with SHPT: a network meta-analysis

Contact Info

Product

Resources

About